Amgen Q3 FY2026 results
$465.67−0.30%
Amgen reported revenue of $10.4 billion, up 8.5% from a year earlier, net income of $3.86 billion and diluted earnings per share of $7.08 against $5.93 for the third quarter of fiscal 2026 (the three months to 30 Sep 2026).
From its quarterly report, the results first announced on 3 Nov 2026. Compiled and checked by AapWire.
Q3 FY2026 against Q3 FY2025
Three months to 30 Sep 2026, against the three months to 30 Sep 2025. Amounts in USD.
| Measure | Q3 FY2026 | Q3 FY2025 | Change |
|---|---|---|---|
| Revenue | $10.37B | $9.56B | +8.5% |
| Gross profit | $7.58B | $6.47B | +17.0% |
| Gross margin | 73.1% | 67.8% | +5.4 pts |
| Operating income | $3.71B | $2.53B | +46.9% |
| Operating margin | 35.8% | 26.4% | +9.4 pts |
| Net income | $3.86B | $3.22B | +20.1% |
| Diluted EPS | $7.08 | $5.93 | +19.4% |
| Operating cash flow | $4.24B | $4.68B | −9.5% |
| Capital expenditure | $587.0M | $436.0M | +34.6% |
| Free cash flow | $3.65B | $4.25B | −14.0% |
Operating KPIs for the quarter
| KPI | Q3 FY2026 | Change on a year |
|---|---|---|
| Product sales | $9.9B | up 8.2% |
| Repatha revenue | $1.1B | up 36.6% |
| EVENITY revenue | $751.0M | up 38.8% |
| Prolia revenue | $632.0M | down 44.5% |
| ENBREL revenue | $611.0M | up 5.3% |
| TEZSPIRE revenue | $538.0M | up 42.7% |
| TEPEZZA revenue | $526.0M | down 6.1% |
| BLINCYTO revenue | $496.0M | up 26.5% |
| Otezla revenue | $481.0M | down 17.8% |
| Nplate revenue | $472.0M | up 3.3% |
| UPLIZNA revenue | $451.0M | up 191.0% |
| KRYSTEXXA revenue | $419.0M | up 30.9% |
| IMDELLTRA/IMDYLLTRA revenue | $406.0M | up 128.1% |
| Vectibix revenue | $335.0M | up 18.0% |
| KYPROLIS revenue | $330.0M | down 8.1% |
| Aranesp revenue | $329.0M | down 7.8% |
| XGEVA revenue | $288.0M | down 46.6% |
Earlier quarters
| Quarter | Period end | Revenue | Change on a year | Diluted EPS |
|---|---|---|---|---|
| Q3 FY2026 | 30 Sep 2026 | $10.37B | +8.5% | $7.08 |
| Q2 FY2026 | 30 Jun 2026 | $10.05B | +9.5% | $4.37 |
| Q1 FY2026 | 31 Mar 2026 | $8.62B | +5.8% | $3.34 |
| Q4 FY2025 | 31 Dec 2025 | $9.87B | +8.6% | $2.46 |
| Q3 FY2025 | 30 Sep 2025 | $9.56B | +12.4% | $5.93 |
| Q2 FY2025 | 30 Jun 2025 | $9.18B | +9.4% | $2.65 |
| Q1 FY2025 | 31 Mar 2025 | $8.15B | +9.4% | $3.20 |
| Q4 FY2024 | 31 Dec 2024 | $9.09B | +10.9% | $1.16 |
More on Amgen: financial statements · revenue · earnings per share
AMGN's results, as they are filed.
Releases read within minutes, guidance against results, the quarter in its eight-quarter history, and an alert on each new report.